Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
StageZero Life Sciences Ltd (TSE:SZLS)
TSX:SZLS
Holding TSE:SZLS?
Track your performance easily
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2018
|% Change Since: -50.00%
|Next Earnings Date:Aug 15, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture for StageZero. While there were significant achievements in expanding partnerships and improving gross margins, challenges such as delayed financial filings and revenue declines due to staffing issues were highlighted. The company is focusing on its Aristotle program and expects positive revenue outcomes from its recent strategic initiatives.Company Guidance
During the StageZero Life Sciences Q1 2024 earnings call, CEO James Howard-Tripp provided guidance on several key areas. The company experienced a decline in Q1 revenue due to staff illness, but anticipates recovery as backlog issues are resolved. A significant focus is on Aristotle, their multi-cancer diagnostic tool, with increased partnerships expected to drive revenue growth. The company also reported a substantial increase in gross margin to 58% and outlined plans to expand into Europe with the Care Oncology protocol 2.0. Revenue potential was discussed, highlighting a $949 fee per Aristotle test and a combined offering with AVRT for $795, aiming to enhance their integrated cancer screening and treatment approach. The company is also preparing for regulatory approval to expand Aristotle into Europe and is pursuing funding for the METRICS study. Guidance was provided through written questions to facilitate broader communication.Partnership Expansion
StageZero added new lab and clinic groups across the U.S. and Canada, focusing on expanding their reach and revenue potential with their Aristotle and AVRT programs.
Gross Margin Improvement
StageZero reported a significant increase in gross margin to 58%, indicating better cost management and efficiency compared to other lab groups.
Launch of Upgraded COC Protocol 2.0
StageZero is preparing for the launch of the upgraded COC protocol 2.0 in Europe, expanding their business development and partnership opportunities.
Business Development in Europe
Formalized business development initiatives in Europe with a focus on expanding the reach of Aristotle, targeting a market of 780 million people.
Potential Revenue from Aristotle
Aristotle test pricing at USD 949 per test, with significant revenue potential from 1,000 patients generating $1 million.
---
TSE:SZLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:SZLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | C$0.04 | C$0.04 | 0.00% |
| Oct 01, 2024 | C$0.04 | C$0.04 | 0.00% |
| May 17, 2024 | C$0.04 | C$0.04 | 0.00% |
| Mar 28, 2024 | C$0.06 | C$0.05 | -16.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does StageZero Life Sciences Ltd (TSE:SZLS) report earnings?
StageZero Life Sciences Ltd (TSE:SZLS) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is StageZero Life Sciences Ltd (TSE:SZLS) earnings time?
StageZero Life Sciences Ltd (TSE:SZLS) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:SZLS EPS forecast?
Currently, no data Available
---